º£½ÇÊÓÆµ

Oops.

Our website is temporarily unavailable in your location.

We are working hard to get it back online.

PRIVACY
Enterprise

AstraZeneca halts vaccine plant expansion citing insufficient government support

The pharmaceutical giant said it was no longer pursuing a £450 million investment in a vaccine manufacturing plant in Merseyside after discussions with the Government

Corporate logos are seen outside the Macclesfield factory of AstraZeneca (Image: Getty Images)

AstraZeneca has scrapped a £450 million investment in a vaccine manufacturing plant in Merseyside, citing Labour's failure to match the support offered by the previous government.

This move overturns an announcement made by then-chancellor Jeremy Hunt during last year's March budget, which would have seen the pharmaceutical giant expand its Speke facility.

The Conservative government at the time claimed the investment would enhance the º£½ÇÊÓÆµ's life sciences sector and bolster public health protection and pandemic readiness.

On Friday, an AstraZeneca spokesperson confirmed the cancellation, stating: "Following discussions with the current Government, we are no longer pursuing our planned investment in Speke."

They added that "Several factors have influenced this decision including the timing and reduction of the final offer compared to the previous government’s proposal."

Despite the reversal, the existing facility will remain operational, and there are no job losses expected.

A Government spokesperson said a “change in the make-up of the investment” proposed by AstraZeneca had “led to a reduced Government grant offer being put forward”.

The spokesperson added: “All Government grant funding has to demonstrate value for the taxpayer and unfortunately, despite extensive work from Government officials, it has not been possible to achieve a solution.